The FDA Cut Ambien's Dose for Women in Half Because of What Was Left in the Blood at 8 a.m.

Eight hours after a 10 mg dose of immediate-release zolpidem, about 15 percent of women and 3 percent of men still had more than 50 nanograms per milliliter in their blood, a concentration tied to impaired driving. With the extended-release tablet the shares were 33 percent of women and 25 percent of men. Those figures, from FDA data as summarized in the Primary Care Companion for CNS Disorders, sit behind the agency’s January 2013 decision to lower the recommended dose for women from 10 mg to 5 mg (Ambien, Edluar, Zolpimist) and from 12.5 mg to 6.25 mg (Ambien CR).

The agency’s reasoning has two parts. Women eliminate zolpidem more slowly than men, so the same tablet leaves more of it in the morning. And the people carrying it around often feel fine. The FDA’s notice said patients can be impaired while feeling fully awake.

Why a clear head is poor evidence

A blood concentration is not something anyone can sense. Waking grogginess is, and the two can coexist in the same person at the same moment. Sleep-inertia research adds that the fog after waking can last for hours, so a sedative that leaves a trace has a lot of ordinary grogginess to hide behind. A driver who rates themselves alert at 7 a.m. has measured their mood.

That is why the label language is written around time in bed. The prescribing information says to take the pill only when a full night is available, which it puts at 7 to 8 hours. A tablet swallowed at 2 a.m. with a 6 a.m. alarm gives the drug about four hours to clear before the car keys come out.

The 2019 warning is about a different hazard

Six years later the FDA added a boxed warning for complex sleep behaviors to zolpidem and two related drugs. That one covers what happens during the night, when a partly asleep brain runs the body through familiar routines. Readers who wake with no memory of how they got somewhere may recognize the shape of confusional arousals, which have other causes and deserve a conversation with a clinician in either case.

Where these numbers stop

The percentages describe studied groups at one time point after one dose. Weight, liver function, age, other medicines and alcohol all move an individual’s level, and the data say little about someone who takes a pill at 11 p.m. versus 4 a.m. Dosing guidance changes with new labels, so the current prescribing information outranks anything written here. This article makes no argument for or against taking the medication.

Four things people ask after the label change

Can I drive the day after taking Ambien CR?

The FDA’s May 2013 label advice says no for the extended-release tablet: patients taking Ambien CR, at either 6.25 mg or 12.5 mg, should not drive or do other tasks needing complete mental alertness the day after taking it, because the risk of next-morning impairment is highest with that form.

Does the lower dose apply to men?

Only as a suggestion. In 2013 the FDA told manufacturers to recommend that prescribers consider the lower doses (5 mg immediate-release, 6.25 mg extended-release) for men, while the women’s dose was lowered outright because women clear zolpidem more slowly.

Why was Intermezzo left out of the dose cut?

Intermezzo is a lower-dose zolpidem tablet approved for waking in the middle of the night, and its doses were already below the new ceilings, so the FDA left them unchanged in 2013.

What did the 2019 boxed warning add?

In April 2019 the FDA required its most serious warning on zolpidem, eszopiclone (Lunesta) and zaleplon (Sonata) for complex sleep behaviors such as sleepwalking, sleep-driving and preparing food while not fully awake, including cases that ended in serious injury or death. It concerns the night, not the morning after.